Fibricor

(fenofibric acid)

Phase 2Small molecule

MMaisonneuve-Rosemont Hospital

Fibricor is one of 43 small molecule programs targeting Medulloblastoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

MedulloblastomaActive, not recruiting

MedulloblastomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

81 competitors in Medulloblastoma

#DrugCompanyPhaseTrials

Oncovin

Eli Lilly

Phase 3

7 2

Cytoxan

BBaxter Healthcare Corporation

Phase 3

16 3

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

14 4

Ceenu

AAzurity Pharmaceuticals

Phase 3

10 5

Oncovin

EEastern Cooperative Oncology Group

Phase 3

9 6

Paraplatin

AAvyxa

Phase 3

4 7

Mesnex

BBaxter Healthcare Corporation

Phase 3

2 8

Glucophage

EMD Serono

Phase 3

1 9

Accutane

CConrado Roberto Hoffmann Filho

Phase 3

1 10

Erivedge

Roche

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

Phase 2Recruiting

Medulloblastoma

NCT01356290

Clinical

Trials by Indication[1]

Interaction3 trials

Drug-Drug Interaction Study Between Fenofibric Acid and Efavirenz

Completed·MMutual Pharmaceutical Company, Inc.·Phase 1·NCT00960570·30 enrolled

Pharmacokinetics and Drug Interaction Study Between Rosuvastatin and Fenofibric Acid in Healthy Male Volunteers

Completed· Daewoong Pharmaceutical Co. LTD. logo

Daewoong Pharmaceutical Co. LTD.·Phase 1·NCT01964365·30 enrolled

A Drug-Drug Interaction Study Between Fenofibric Acid and Efavirenz

Completed·MMutual Pharmaceutical Company, Inc.·Phase 1·NCT01472380·30 enrolled

Lip1 trial

To Compare Safety and Pharmacokinetic Properties of CJ-30039 and Lipidil Supra

Completed·HHK inno.N Corporation·Phase 1·NCT01501435·48 enrolled

Medulloblastoma1 trial

Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors

Recruiting·MMedical University of Vienna·Phase 2·NCT01356290·232 enrolled

TED1 trial

Fasted Pharmacokinetic and Bioequivalency Study of Fenofibric Acid

Completed·MMutual Pharmaceutical Company, Inc.·Phase 1·NCT00961259·54 enrolled

Fed1 trial

Fed Bioequivalence Study of Fenofibric Acid Versus TriCor® (Fenofibrate)

Completed·MMutual Pharmaceutical Company, Inc.·Phase 1·NCT00960687·54 enrolled

1 more indication

Unspecified3 trials

Four Arm Food Effect Study of Fenofibric Acid Tablets

Completed·MMutual Pharmaceutical Company, Inc.·Phase 1·NCT00960856·40 enrolled

Diazoxide Choline Controlled-Release Tablet (DCCR) for Very High Triglycerides

Withdrawn·EEssentialis, Inc.·Phase 3·NCT00973271

Bioequivalence Study of Fenofibric Acid Versus Tricor® (Fenofibrate)

Completed·MMutual Pharmaceutical Company, Inc.·Phase 1·NCT00961116·54 enrolled

Regulatory

FDA Approval Timeline[4]

Aug 14, 2009

FIBRICOR

NDA NDA022418

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for fenofibric acid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — fenofibric acid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for fenofibric acid. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA022418). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Fibricor. U.S. Food & Drug Administration.
[6]
SEC EDGAR — Maisonneuve-Rosemont Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMaisonneuve-Rosemont Hospital

Patent Landscape[5]

Patent Cliff

Aug 20, 2027

Earliest patent expiration — generic entry possible after this date

Patent #Expires

7569612Aug 20, 2027

7741374Aug 20, 2027

7741373Aug 20, 2027

7915247Aug 20, 2027

Fibricor

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2030

Trials by Indication[1]

Interaction3 trials

Lip1 trial

Medulloblastoma1 trial

TED1 trial

Fed1 trial

Unspecified3 trials

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Related News